More specifically, it was shown that serum GFAP concentration early after ischemic stroke onset correlates well with ischemic lesion size and clinical severity among stroke survivors and appears to be a useful biomarker of poor prognosis in the case of AIS. The gene discussed is GFAP; the disease is Stroke.